ONO-4578 + nivolumab + mFFX

**ONO-4578 + nivolumab + mFFX** is a triple combination regimen comprising ONO-4578 (a highly selective antagonist of prostaglandin E2 receptor EP4), nivolumab (a programmed death-1 [PD-1] immune checkpoint inhibitor), and modified FOLFIRINOX (mFFX; a chemotherapeutic regimen including fluorouracil, leucovorin, irinotecan, and oxaliplatin)[1][5]. - **ONO-4578** acts by blocking EP4 receptor-mediated immunosuppression, enhancing antitumor immune response[1][2]. - **Nivolumab** inhibits PD-1, releasing the inhibition of T-cell–mediated cancer cell killing[1][2][3][4]. - **mFFX** is a multi-agent chemotherapy regimen standard for pancreatic and other metastatic cancers[5]. This combination is developed for first-line treatment in metastatic pancreatic cancer and other advanced solid tumors[5].

Brand names

Opdivo (for nivolumab)mFOLFIRINOX (for mFFX, sometimes referenced as the regimen)

Other names

4578+NIV+mFFXONO-4578-04 regimenONO4578-04 regimenONO 4578-04 regimen